<?xml version="1.0" encoding="UTF-8"?><xmi:XMI xmlns:xmi="http://www.omg.org/XMI" xmlns:pos="http:///de/tudarmstadt/ukp/dkpro/core/api/lexmorph/type/pos.ecore" xmlns:tcas="http:///uima/tcas.ecore" xmlns:cas="http:///uima/cas.ecore" xmlns:tweet="http:///de/tudarmstadt/ukp/dkpro/core/api/lexmorph/type/pos/tweet.ecore" xmlns:type8="http:///org/apache/uima/ruta/type.ecore" xmlns:morph="http:///de/tudarmstadt/ukp/dkpro/core/api/lexmorph/type/morph.ecore" xmlns:dependency="http:///de/tudarmstadt/ukp/dkpro/core/api/syntax/type/dependency.ecore" xmlns:type6="http:///de/tudarmstadt/ukp/dkpro/core/api/semantics/type.ecore" xmlns:type9="http:///org/apache/uima/trials/type.ecore" xmlns:noNamespace="http:///uima/noNamespace.ecore" xmlns:type="http:///de/tudarmstadt/ukp/dkpro/core/api/anomaly/type.ecore" xmlns:type7="http:///de/tudarmstadt/ukp/dkpro/core/api/syntax/type.ecore" xmlns:type3="http:///de/tudarmstadt/ukp/dkpro/core/api/metadata/type.ecore" xmlns:type4="http:///de/tudarmstadt/ukp/dkpro/core/api/ner/type.ecore" xmlns:type5="http:///de/tudarmstadt/ukp/dkpro/core/api/segmentation/type.ecore" xmlns:type2="http:///de/tudarmstadt/ukp/dkpro/core/api/coref/type.ecore" xmlns:constituent="http:///de/tudarmstadt/ukp/dkpro/core/api/syntax/type/constituent.ecore" xmlns:chunk="http:///de/tudarmstadt/ukp/dkpro/core/api/syntax/type/chunk.ecore" xmi:version="2.0"><cas:NULL xmi:id="0"/><tcas:DocumentAnnotation xmi:id="2" sofa="1" begin="0" end="1710" language="x-unspecified"/><type9:ORR xmi:id="3" sofa="1" begin="865" end="870"/><type9:ORR xmi:id="4" sofa="1" begin="1157" end="1162"/><type9:ORR xmi:id="7" sofa="1" begin="1505" end="1510"/><type9:PFSMean xmi:id="5" sofa="1" begin="988" end="998"/><type9:OSMean xmi:id="6" sofa="1" begin="1031" end="1041"/><cas:Sofa xmi:id="1" sofaNum="1" sofaID="_InitialView" mimeType="text" sofaString="PURPOSE: Amrubicin is a synthetic anthracycline with potent topoisomerase II&#13;&#10;inhibition. This phase II study was conducted to confirm safety and activity of&#13;&#10;amrubicin in the treatment of refractory small-cell lung cancer (SCLC).&#13;&#10;PATIENTS AND METHODS: Patients with refractory SCLC (either with progressive&#13;&#10;disease as best response or progression within 90 days of first-line therapy)&#13;&#10;received amrubicin (40 mg/m(2)/d for 3 every 21 days). The primary end point was &#13;&#10;overall response rate (ORR); secondary end points included progression-free&#13;&#10;survival (PFS), overall survival (OS), and change in left ventricular ejection&#13;&#10;fraction (LVEF).&#13;&#10;RESULTS: Seventy-five patients with a median progression-free interval after&#13;&#10;first-line therapy of 38 days were enrolled; 69 patients received a median of&#13;&#10;four amrubicin cycles (range, one to 12 cycles). The ORR was 21.3% (95% CI, 12.7%&#13;&#10;to 32.3%), with one complete response (1.3%) and 15 partial responses (20%).&#13;&#10;Median PFS and OS were 3.2 months (95% CI, 2.4 to 4.0 months) and 6.0 months (95%&#13;&#10;CI, 4.8 to 7.1 months), respectively. The ORR in 43 patients who never responded &#13;&#10;to first-line therapy was 16.3% (95% CI, 6.8% to 30.7%). Most commonly reported&#13;&#10;grade 3 or 4 adverse events included neutropenia (67%), thrombocytopenia (41%),&#13;&#10;and anemia (30%), with febrile neutropenia in 12%. There was no decrease in mean &#13;&#10;LVEF with cumulative amrubicin doses exceeding 750 mg/m(2).&#13;&#10;CONCLUSION: Single-agent amrubicin showed promising activity with a 21.3% ORR and&#13;&#10;an acceptable safety profile when used as second-line therapy patients with&#13;&#10;platinum-refractory SCLC. Amrubicin did not induce early cardiotoxicity, but its &#13;&#10;long-term effects are unknown."/><cas:View sofa="1" members="2 3 4 7 5 6"/></xmi:XMI>